Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Payables (2017 - 2025)

Arcus Biosciences has reported Payables over the past 9 years, most recently at $42.0 million for Q4 2025.

  • Quarterly results put Payables at $42.0 million for Q4 2025, up 133.33% from a year ago — trailing twelve months through Dec 2025 was $42.0 million (up 133.33% YoY), and the annual figure for FY2025 was $42.0 million, up 133.33%.
  • Payables for Q4 2025 was $42.0 million at Arcus Biosciences, roughly flat from $42.0 million in the prior quarter.
  • Over the last five years, Payables for RCUS hit a ceiling of $42.0 million in Q3 2025 and a floor of $10.0 million in Q4 2021.
  • Median Payables over the past 5 years was $17.5 million (2023), compared with a mean of $20.3 million.
  • Biggest five-year swings in Payables: soared 911.71% in 2021 and later tumbled 45.41% in 2023.
  • Arcus Biosciences' Payables stood at $10.0 million in 2021, then skyrocketed by 100.0% to $20.0 million in 2022, then decreased by 15.0% to $17.0 million in 2023, then grew by 5.88% to $18.0 million in 2024, then surged by 133.33% to $42.0 million in 2025.
  • The last three reported values for Payables were $42.0 million (Q4 2025), $42.0 million (Q3 2025), and $29.0 million (Q2 2025) per Business Quant data.